6 days Ago By Defense World Staff
Legal & General Group Plc cut its stake in shares of Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 122,393 shares of the company’s stock after selling 16,553 shares during the quarter. Legal & General Group Plc’s holdings in Maravai LifeSciences were worth $667,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently modified their holdings of the stock.
Performa Ltd US LLC increased its holdings in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,300 shares during the period.
FNY Investment Advisers LLC grew its position in shares of Maravai LifeSciences by 600.0% during the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after buying an additional 6,000 shares in the last quarter.
Farther Finance Advisors LLC increased its stake in shares of Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after buying an additional 9,916 shares during the period.
Cibc World Markets Corp bought a new stake in shares of Maravai LifeSciences in the fourth quarter valued at about $56,000. Finally, Atria Investments Inc purchased a new stake in Maravai LifeSciences in the fourth quarter worth about $58,000. Institutional investors own 50.
25% of the company’s stock. Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on MRVI. Robert W.
Baird cut shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th.
Baird R W downgraded Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Bank of America decreased their price objective on Maravai LifeSciences from $9.00 to $8.
00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Morgan Stanley cut their target price on Maravai LifeSciences from $7.00 to $5.
00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 25th. Finally, Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research report on Friday, March 21st.
One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $6.34.
Maravai LifeSciences Trading Down 2.0 % Shares of Maravai LifeSciences stock opened at $2.01 on Tuesday.
The firm’s 50 day simple moving average is $2.41 and its two-hundred day simple moving average is $4.56.
The firm has a market capitalization of $511.22 million, a price-to-earnings ratio of -1.23 and a beta of 0.
18. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.
67 and a 12-month high of $11.56. The company has a current ratio of 10.
74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.
Insider Transactions at Maravai LifeSciences In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.
00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54.
The trade was a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website .
Company insiders own 0.63% of the company’s stock. Maravai LifeSciences Company Profile ( Free Report ) Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Featured Articles Five stocks we like better than Maravai LifeSciences What is a Bond Market Holiday? How to Invest and Trade Best Defense Stocks in 2025..
. So Far Top Stocks Investing in 5G Technology Alphabet Rebounds After Strong Earnings and Buyback Announcement 3 Stocks to Consider Buying in October Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc.
( NASDAQ:MRVI – Free Report ). Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
